Lytica Therapeutics is a biotech company based in Cambridge that is dedicated to developing novel peptide conjugates for next-generation antibody-drug conjugates (ADCs). They believe that the secret to unlocking more effective ADCs lies in the payload. Unlike traditional ADCs, Lytica's conjugates combine targeted antibodies with cytotoxic payloads, imbuing antibodies with new therapeutic properties.

The company's stapled peptide platform allows for rapid exploration of ADC combinations, making the drug development process faster and more efficient. The modularity of their peptides and the stabilizing properties of peptide stapling also make Lytica's payloads highly compatible with existing antibody and linker technologies. This compatibility increases the potential for successful drug targeting and offers new possibilities for previously undruggable targets.

Lytica's team is composed of industry experts with extensive experience in stapled peptides and ADC technology. Their leadership, scientific officers, and research associates are committed to pushing the boundaries of ADC technology forward. Additionally, Lytica partners with pharma leaders to enhance ADC therapeutic value using smart payloads.

If you are interested in joining Lytica Therapeutics' journey to develop the ADCs of the future, they welcome you to explore their career opportunities. Contact them via their website or visit their headquarters in Cambridge, MA